The portfolio maintains a sizable cost advantage over competitors, priced within the least expensive fee quintile among peers.
Global X Genomics & Biotechnology ETF GNOM
Morningstar’s Analysis GNOM
Will GNOM outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 48.0
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Natera Inc | 8.45 | 7.5 Mil | Healthcare |
Moderna Inc | 5.13 | 4.5 Mil | Healthcare |
CRISPR Therapeutics AG | 5.09 | 4.5 Mil | Healthcare |
Ultragenyx Pharmaceutical Inc | 4.95 | 4.4 Mil | Healthcare |
Agilent Technologies Inc | 4.89 | 4.3 Mil | Healthcare |
Sarepta Therapeutics Inc | 4.40 | 3.9 Mil | Healthcare |
Qiagen NV | 4.01 | 3.5 Mil | Healthcare |
Illumina Inc | 3.93 | 3.5 Mil | Healthcare |
Bio-Techne Corp | 3.79 | 3.4 Mil | Healthcare |
Biomarin Pharmaceutical Inc | 3.72 | 3.3 Mil | Healthcare |